Litcius/Paper detail

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

Christian Pfister, Gwénaëlle Gravis, Aude Fléchon, M. Soulié, Laurent Guy, Brigitte Laguerre, Nicolas Mottet, Florence Joly, Yves Allory, Valentin Harter, Stéphane Culine

2020European Urology247 citationsDOIOpen Access PDF

Topics & Concepts

MedicineVinblastineGemcitabineBladder cancerInternal medicineClinical endpointNeoadjuvant therapyChemotherapyUrologyPerioperativeSurrogate endpointCommon Terminology Criteria for Adverse EventsOncologyAntimetaboliteSurgeryRandomized controlled trialCancerBreast cancerBladder and Urothelial Cancer TreatmentsCancer, Stress, Anesthesia, and Immune ResponseIntraperitoneal and Appendiceal Malignancies
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses | Litcius